96. クローン病
[臨床試験数:2,209,薬物数:1,276(DrugBank:240),標的遺伝子数:166,標的パスウェイ数:210

Searched query = "Crohn disease", "Terminal ileitis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Search in Page e.g. "Phase 3", "Not recruiting", "Japan"
5 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT01181765
(ClinicalTrials.gov)
June 201212/8/2010The Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera EndoscopyThe Efficacy of Open Label Infliximab for the Induction and Maintenance of Mucosal Healing in Small Bowel Crohn's Disease Assessed Through Wireless Camera Endoscopy (the ICE Study)Crohn's DiseaseBiological: Infliximab 5 mg/kg body weight infused over 2 hoursJanssen Inc.NULLCompleted18 YearsN/ABoth1Phase 4Canada
2JPRN-UMIN000002604
2009/05/0101/11/2009Combined therapy of infliximab with surgery in maintenance of remission in Crohn's disease Crohn's diseasePatients are randomly divided into two groups, groups treated with or without infliximab by staffs of Keio Clinical Research Center at 2 to 4 weeks after surgery.
Patients receive infliximab 5 mg/kg at 0, 2, 6 weeks, followed by every 8 weeks for 2 years. Alternatively, patients continue to receive infliximab with intervals of 8 weeks if they received infliximab within 8 weeks from the time point 0.
Patients without infliximab receive maintenance therapy without immunomodulators.
Clinical Research Group of inflammatory bowel disease in JapanNULLComplete: follow-up complete18years-oldNot applicableMale and Female100Phase 4Japan
3NCT00752622
(ClinicalTrials.gov)
November 200812/9/2008Treatment With Infliximab in a Medical Setting (Study P05587)Optimization of Treatment With Infliximab in a Medical SettingCrohn's DiseaseBiological: Infliximab 5 mg/kg;Biological: Infliximab 5 mg/kg every 6 weeks;Biological: Infliximab 7 mg/kg every 8 weeksMerck Sharp & Dohme Corp.NULLTerminated18 YearsN/AAll100Phase 4Canada
4NCT00269841
(ClinicalTrials.gov)
May 199622/12/2005An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's DiseaseA Placebo-Controlled, Repeated-Dose Study of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Enterocutaneous Fistulae as a Complication of Crohn's DiseaseCrohn DiseaseDrug: Infliximab 10 mg/kg;Drug: Infliximab 5 mg/kg;Drug: PlaceboCentocor, Inc.NULLCompleted18 Years65 YearsBoth94Phase 3NULL
5NCT00269854
(ClinicalTrials.gov)
June 199522/12/2005An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Crohn's DiseaseA Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn's DiseaseCrohn DiseaseDrug: Infliximab 5 mg/kg;Drug: Infliximab 10 mg/kg;Drug: Infliximab 20 mg/kg;Drug: PlaceboCentocor, Inc.NULLCompleted18 Years65 YearsBoth108Phase 2;Phase 3NULL